Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

IMRT and Primary Transoral Surgery in the Treatment of Squamous Cell Carcinomas

Recruiting

Conditions: Squamous Cell Carcinoma

Interventions: Procedure: transoral resection
Radiation: IMRT

First Posted Date: 2020-01-13

Last Posted Date: 2024-11-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 150

Registration Number: NCT04224389

Locations: 🇫🇷
Centre Hospitalier InterCommunal, Créteil, France
🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷
Hôpital la Croix Rousse, Lyon, France

and more 13 locations

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Phase 3

Recruiting

Conditions: High-Risk Neuroblastoma
Patient With Insufficient Response Chemoimmunotherapy

Interventions: Radiation: Radiotherapy
Drug: Vincristine
Drug: Busulfan
Drug: Dinutuximab Beta
Drug: Carboplatin
Drug: Melphalan
Drug: Etoposide
Drug: Thiotepa
Drug: Vindesine
Drug: Dacarbazine
Drug: Ifosfamide
Drug: Doxorubicin
Drug: Cisplatin
Drug: Temozolomide 100 MG
Drug: Irinotecan
Drug: Cyclophosphamid

First Posted Date: 2020-01-09

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 800

Registration Number: NCT04221035

Locations: 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷
Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹
instituto Giannina Gaslini genova, Genova, Italy

and more 134 locations

Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs

Not Applicable

Recruiting

Conditions: Cancer

Interventions: Procedure: Blood sample

First Posted Date: 2019-06-13

Last Posted Date: 2024-08-14

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1240

Registration Number: NCT03984318

Locations: 🇫🇷
Gustave Roussy, Chevilly-Larue, France
🇫🇷
Hôpital Paul Brousse, Villejuif, France
🇫🇷
Hôpital Bicêtre, Le Kremlin-Bicêtre, France

and more 1 locations

Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults

Phase 3

Recruiting

Conditions: Mucositis Oral

Interventions: Other: Placebo
Device: Low-Level Laser Therapy

First Posted Date: 2019-06-12

Last Posted Date: 2023-05-30

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 315

Registration Number: NCT03983369

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷
Institut Curie, Paris, France
🇫🇷
Centre Oscar Lambret, Lille, France

and more 2 locations

Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors

Phase 2

Withdrawn

Conditions: Triple Negative Breast Cancer
Prostate Adenocarcinoma
Esophageal Adenocarcinoma
Metastatic Colorectal Cancer
Stomach Adenocarcinoma

Interventions: Drug: Tremelimumab
Drug: Durvalumab

First Posted Date: 2019-06-11

Last Posted Date: 2023-01-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Registration Number: NCT03982173

Video-Based Cognitive Behavioral Therapy for Insomnia in Adults Cancer Patients and Survivors

Not Applicable

Completed

Conditions: Insomnia

Interventions: Other: Questionnaires

First Posted Date: 2019-06-11

Last Posted Date: 2019-06-11

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 177

Registration Number: NCT03981666

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy

Phase 1

Withdrawn

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: FOLFOX regimen
Drug: Nivolumab
Drug: GLA-SE
Drug: Ipilimumab

First Posted Date: 2019-06-11

Last Posted Date: 2020-02-17

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Registration Number: NCT03982121

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

Phase 3

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Acetylsalicylic acid
Drug: Atorvastatin

First Posted Date: 2019-01-28

Last Posted Date: 2024-11-29

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1210

Registration Number: NCT03819101

Locations: 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
Bellinzona Istituto Oncologico, Bellinzona, Switzerland
🇨🇭
Kantonsspital Baselland, Bruderholz, Switzerland

and more 17 locations

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

Phase 2

Active, not recruiting

Conditions: Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

Interventions: Drug: Nivolumab cohort 1
Drug: Nivolumab cohort 2

First Posted Date: 2018-10-11

Last Posted Date: 2024-11-28

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 45

Registration Number: NCT03703050

Locations: 🇫🇷
CHU Bordeaux, Bordeaux, France
🇫🇷
CHU Mondor, Créteil, France
🇫🇷
Centre Oscar Lambret, Lille, France

and more 10 locations

Study of a Simplified Geriatric Evaluation Performed by Oncologists Prior to Cancer Treatment by Radiotherapy or Chemotherapy in Subjects Aged 70 Years or Older With Inoperable Squamous Cell Cancer of the Head and Neck

Conditions: Inoperable Squamous Cell Cancer of the Head and Neck

Interventions: Other: Geriatric Screening Test G8
Other: Geriatric fragility test GERICO

First Posted Date: 2018-08-03

Last Posted Date: 2018-08-03

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 800

Registration Number: NCT03614936

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy